medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2017, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2017; 64 (2)

Study to evaluate the efficacy and safety of nitazoxanide in the treatment of intestinal parasitosis

Romero-Cabello R, Gándara-Ramírez JL, Romero-Feregrino R, Navarrete-Cadena E

Language: Spanish
References: 11
Page: 73-78
PDF size: 295.97 Kb.


ABSTRACT

Nitazoxanide has been used as a broad-spectrum antiparasitic; one part is absorbed and another remains in the intestine, having intraluminal action, and its metabolite tizoxanide, extra-intestinal activity; it is eliminated by feces, bile and urine. This study aimed to evaluate the therapeutic efficacy of nitazoxanide. We studied children from five to 12 years of age, adolescents and adults from 12 to 65 years, of both genders; a total of 200 patients with intestinal parasitosis. Nitazoxanide was given to children in suspension, 200 mg/12 hours, and to adolescents and adults in tablets, 500 mg/12 hours, for three days. Coproparasitoscopic controls and clinical evaluations were performed. Parasitic eradication was achieved in 174 cases (87%), and it was not successful in 26 (13%). Eradication of protozoa was total, and it was partially effective for helminthes.


REFERENCES

  1. Rossignol JF, Cavier R. New derivative of 2-benzamido-5-nitrothiazoles. Chem Abstr. 1975; 83: 28216n.

  2. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother. 1996; 40 (10): 2266-2270.

  3. Euzaby J, Prom Tep S, Rossignol JF. Experimentation des propietes anthelminthiques de la nitazoxanida chez le chien, le chat et les ovins. Reveu de Medicine Veterinaire. 1980; 131: 687-696.

  4. Romero-Cabello R, Guerrero LR, Muñóz-García MR, Geyne-Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med Hyg. 1997; 91 (6): 701-703.

  5. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg. 1984; 33 (3): 511-512.

  6. Doumbo O, Rossignol JF, Pichard E, Traore HA, Dembele TM, Diakite M et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg. 1997; 56 (6): 637-639.

  7. Theodos CM, Griffiths JK, D’Onfro J, Fairfield A, Tzipori S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother. 1998; 42 (8): 1959-1965.

  8. Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg. 1998; 92 (1): 103-104.

  9. Padilla-Raygoza N, Alarcón-Ginori A, Figueroa-Ferrari RC, Muñoz-Rodríguez M. Comparación del efecto de la quinfamida+ y de la nitazoxanida en el tratamiento de la amibiasis intestinal no disentérica, en niños. Rev Mex Pediatr. 1998; 65 (5): 196-199.

  10. Murphy JR, Friedmann JC. Pre-clinical toxicology of nitazoxanide —a new antiparasitic compound. J Appl Toxicol. 1985; 5 (2): 49-52.

  11. Stockis A, Deroubaix X, Lins R, Jeanbaptiste B, Calderon P, Rossignol JF. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int J Clin Pharmacol Ther. 1996; 34 (8): 349-351.




2020     |     www.medigraphic.com